INTRODUCTION

Gastric cancer (GC) is one of the most prevalent malignancies causing mortality worldwide. It remains among the top 10 causes of cancer-related death for both genders in many Asian countries. The primary therapeutic method for resectable GC is gastrectomy, which generally causes considerable metabolic stress to patients. To modulate cell function, maintain homeostasis of the immune response, reduce postoperative complications, and obtain favorable outcomes, physicians prescribe specific nutrients with immunomodulatory properties as supplementation to enteral or parenteral formulas, indicating immunonutrition. In the formulas, among the immunonutrients, glutamine, arginine, and n-3 polyunsaturated fatty acids are the most commonly used either alone or in combination. The present review summarizes and focuses on the evidence obtained from clinical trials and animal studies supporting the role of immunonutrients supplemented enterally or parenterally in total or subtotal gastrectomy. In addition, this review describes the possible molecular mechanisms underlying the protective action of these immunonutrients, which may contribute to therapeutic approaches to improve postoperative outcomes of gastrectomy. Combination of conventional therapy with immunonutrition seems to be a useful strategy to achieve synergistic effects in the treatment of GC patients.

KEYWORDS
arginine, gastrectomy, glutamine, immunonutrition, n-3 fatty acids
or those who cannot meet 60% of the daily requirement by postoperative day 6 should be given individualized nutritional support.² For all postoperative patients who have a functioning gastrointestinal (GI) tract but cannot tolerate oral intake, standard EN is generally recommended because it is less expensive, safer, and more physiological to maintain the barrier function of the intestines than any artificial nutritional support. Meta-analysis reports suggest that EN is conducive to a lower infection rate and a shorter hospital stay than parenteral nutrition (PN) in GI surgical patients.³,⁴ However, if patients cannot receive adequate EN as a result of GI incompetency such as ileus, bowel ischemia, severe GI bleeding, or critical illness with poor enteral tolerance, then PN is required. In our previous study, we found that compared with patients without nutritional support, morbidity and mortality of malnourished gastrectomy patients with peri- or postoperative total parenteral nutrition (TPN) significantly decreased.⁵

To reduce postoperative complications and achieve immune homeostasis through regulating cell function, physicians introduce enteral or parenteral formulas supplemented with nutrients having immunomodulatory properties. This type of supplementation is termed immunonutrition. Commonly in the formulas, some of the immunonutrients, such as glutamine (GLN), arginine (Arg), n-3 polyunsaturated fatty acids (PUFA), and nucleotides, are supplemented alone or in combination. Previous meta-analyses found that immunonutrition reduces overall postoperative complications and shortens hospital stay in adult patients with major abdominal surgery.⁶,⁷ According to a meta-analysis specifically for total gastrectomy patients with GC, enteral immunonutrition improves cellular immunity, modulates inflammatory response, and reduces postoperative complications.⁸ Previous studies using immunonutritional regimens were conducted using either one specific nutrient or in different combinations of nutritional components. In the present review, we explored and summarized the evidence obtained from clinical trials and animal studies supporting the role of immunonutrients supplemented enterally or parenterally in total or subtotal gastrectomy. This review also describes the possible molecular mechanisms underlying the protective action of these immunonutrients, which may contribute to the therapeutic approaches to improve postoperative outcomes of gastrectomy.

2 | NUTRITIONAL SUPPORT IN PATIENTS WITH GC RECEIVING GASTRECTOMY

2.1 | Effects of specific nutrient combination on gastrectomy

Although immunonutrition has agreeably favorable effects, different time points of intervention may influence the outcomes after gastrectomy. In a previous study, an enteral immune-enhancing formula enriched with Arg, n-3 fatty acids (FA), and ribonucleic acid (RNA), named “Impact (Novartis Nutrition, Bern, Switzerland),” was given to patients with GC in two distinct time periods; then, the potential benefits of perioperative versus postoperative treatments on host defense and protein metabolism were evaluated. Compared with postoperative dosage, perioperative supplementation of immunonutrition had more metabolic advantages in modulating postoperative immune and inflammatory responses in gastrectomy patients with GC.⁹ However, early postoperative EN with Impact supplementation increased collagen synthesis, thereby promoting wound healing¹⁰ and improving the clinical and immunological outcomes of these patients.¹¹ Okamoto et al¹² found that preoperative EN with Impact supplementation maintained CD4⁺ T-cell levels, shortened the duration of systemic inflammatory response syndrome, and decreased the incidence of postoperative infectious complications in patients with GC. In another study, Impact was included in a normal diet for 5 consecutive days before gastrectomy; however, preoperative enteral immunonutrition did not show any benefits in the clinical outcomes of patients with GC.¹³ Meanwhile, a prospective randomized clinical trial showed that routine postoperative immunonutrition given enterally or parenterally had no advantages in well-nourished patients undergoing elective gastrectomy or pancreaticoduodenectomy.¹⁴ Peker et al¹⁵ investigated the effects of immunonutrition on infiltrative lymphocytes and angiogenesis in resected gastric adenocarcinoma tissues. They found that compared with the samples obtained from patients with standard nutrition, the samples from patients consuming Impact for 7 preoperative days resulted in a lower CD4⁺/CD8⁺ ratio and in a higher CD105 level. The low CD4⁺/CD8⁺ ratio in tumor-infiltrating lymphocytes could be an indicator that tumor progression has been prevented. However, CD105 is a marker of microvascular intensity and is used to indicate neovasularity. The abovementioned findings indicated that preoperative immunonutrition regulates the balance between CD4⁺ and CD8⁺ T cells but its prolonged use increases tumor angiogenesis.¹⁶

In a clinical trial, malnourished patients were given preoperative PN for 2 weeks initially. Then, gastrectomy or pancreatectomy patients were randomly assigned to either a postoperative immunomodulating diet or a standard oligopeptide diet. Immunomodulating diet contains n-3 FA, GLN, and Arg as immunonutrients. Consequently, postoperative immunonutrition reduced the overall morbidity and mortality in malnourished surgical patients with cancer.¹⁷ A study carried out by Liu et al¹⁸ used the standard enteral formula enriched with GLN and Arg for 7 days postoperatively in total gastrectomy patients with GC. They found that serum albumin, proalbumin, and transferrin levels, as well as CD4⁺ T cells, natural killer cell percentages, and immunoglobulin levels were elevated prominently. Hence, postoperative immunonutrition improved the patients’ nutritional status and immune function after gastrectomy. A recent study evaluated the effect of immunonutrition on immunomodulatory and anti-inflammatory functions in gastrectomy patients with GC. As a result, the formula enriched with Arg, GLN, n-3 FA, and nucleotide contributed to high levels of CD4⁺ and CD3⁺ T cells and immunoglobulin count, but the levels of inflammatory mediators were low. Thus, postoperative immunonutrition improved immune function and attenuated the inflammatory response in gastrectomy patients with GC.¹⁹ A meta-analysis concluded that among the immunonutrients...
used for enteral immunonutrition, namely, Arg, GLN, n-3 FA, and RNA, RNA and n-3 FA are the most effective in reducing infectious complications and length of hospital stay in patients with GC suffering from gastrectomy. In a rodent sarcopenia model induced by total gastrectomy, Haba et al investigated the effect of oral branched-chain amino acids (BCAA) and/or GLN supplementation on skeletal muscle atrophy after surgery. They found that combined use of BCAA and GLN was more effective in inhibiting muscle atrophy than providing BCAA or GLN alone. Considering that several immunonutrients are combined in enteral immunonutrition formulas, the influence of each immunonutrient on gastrectomy cannot be confirmed. Therefore, we summarized the studies that used the most commonly used immunonutrients, and we describe the roles of these immunonutrients on gastrectomy.

### 2.2 Effects of FA on gastrectomy

Fish oils contain rich sources of n-3 FA, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Numerous clinical trials have shown that fish oil supplementation has anti-inflammatory and immunomodulatory properties. EPA- and DHA-acquired metabolites are associated with a decrease in proinflammatory mediators, and their ability to reduce prostaglandin E₂ production may modulate the release of T helper cell type 2 (Th2) cytokines and elicit highly balanced T-cell subsets during metabolic stress.

A randomized clinical trial compared n-3 FA-supplemented EN with a standard formula for 7 days before and after operation in patients with subtotal esophagectomy or total gastrectomy. Consequently, perioperative enteral immunonutrition with n-3 FA did not affect the clinical outcomes of esophagectomy or total gastrectomy. Moreover, Iida et al investigated the addition of EPA-enriched nutrition to a standard diet in patients with GC undergoing total gastrectomy. Oral supplementation with 2.2 g EPA was provided for 7 preoperative days and 21 postoperative days. Compared with the standard diet, an EPA-enriched oral diet did not influence surgical morbidity and body weight loss after total gastrectomy.

With regard to PN, Makay et al evaluated the effect of postoperative n-3 FA dosage on cellular hypoperfusion associated with major gastric surgery. They found that PN with n-3 FA supplementation did not have a significant effect on lactate clearance and cellular hypoperfusion after major gastrectomy. In a prospective, randomized controlled trial, patients with GC were treated with n-3 FA-rich fish oil fat emulsion or received soybean oil by PN after surgery. Although mean plasma lactate concentration in patients with n-3 FA was higher, the difference was not statistically significant. Further, no difference was observed in the changes of liver and renal functions. Meanwhile, PN based on n-3 FA-rich fish oil fat emulsion alleviated the inflammatory reaction and reduced inflammatory complications after gastrectomy. SMOFlipid (Fresenius Kabi, Bad Homburg, Germany) is an i.v. lipid emulsion with a physical mixture of medium-chain triglycerides (MCT), soybean oil, olive oil, and fish oil. We conducted a study to compare the efficacy of this lipid emulsion with that of MCT/long-chain triglyceride (LCT) in adult patients undergoing GI surgery. Despite the clinical outcomes and inflammatory response being comparable between groups, SMOFlipid had a better triglyceride-lowering effect. Therefore, SMOFlipid may have potential benefits in patients with limited triglyceride elimination capacity.

Some basic animal and cell studies were conducted to investigate the influences of fish oil on gastrectomy. We previously evaluated the effect of n-3 FA-containing PN on immune functions, including leukocyte adhesion molecule expression, circulating lymphocyte subpopulation, intracellular cytokine, and phagocytic activity in rats receiving total gastrectomy. Results showed that parenterally infused fish oil did not lead to immunosuppression. In addition, giving fish oil resulted in a higher CD4⁺ T-cell proportion and CD4⁺/CD8⁺ ratio, enhanced the peritoneal phagocytic activity of macrophages, and reduced leukocyte adhesion molecule expression in rats with total gastrectomy. An in vitro study carried out in our laboratory also showed that EPA and DHA inhibited macrophage-induced GC cell migration, implying the beneficial effects of EPA/DHA in GC treatment. Fat emulsions containing LCT and MCT are commonly used in PN. We previously investigated the effects of pre-infusion with TPN using MCT versus LCT emulsion on inflammatory mediators, hepatic lipids, and antioxidant capacity in rats receiving gastrectomy. Rats were inserted with an internal jugular catheter individually and then received TPN for 5 days. Thereafter, they underwent partial gastrectomy and were killed 24 hours postoperatively. We found that preoperative infusion with MCT/LCT improved hepatic lipid metabolism and reduced oxidative stress after gastrectomy. This aforementioned emulsion comprises structured triacylglycerols (TG) with medium- and long-chain FA randomly distributed within a single TG molecule. This type of fat emulsion is clinically advantageous over LCT and the physical mixture of MCT/LCT emulsions because structured MCT/LCT are cleared faster from the blood and improve nitrogen balance in moderately catabolic patients. Compared with the LCT and MCT/LCT groups, rats given structured MCT/LCT had lower plasma lipid levels and leukocyte integrin expression after total gastrectomy.

### 2.3 Effects of GLN on gastrectomy

Glutamine is the most abundant amino acid in mammalian plasma and intracellular pools. Many important physiological functions depend directly or indirectly on GLN metabolism. GLN is a shuttle for nitrogen transport, an antioxidant precursor, a source of carbon and nitrogen, and an energy source for rapidly proliferating cells. GLN, as a nonessential amino acid, can be synthesized in virtually all tissues of the body. However, under certain catabolic conditions, such as trauma, surgery, or infection, metabolic demands increase, and the ability of GLN production is impaired. GLN obtained from dietary intake and endogenous synthesis becomes insufficient to meet the GLN requirement of the body. GLN may become essential, and additional supplementation is necessary during certain
catabolic states. GLN has elicited considerable attention for its therapeutic role in disease treatment. The beneficial effects of providing exogenous GLN supplementation for metabolically stressful conditions have been extensively studied with positive effects of increasing nitrogen retention, preserving intestinal mucosa integrity and intestinal permeability, and modulating immunological function.

For evaluating the clinical impact of GLN on postoperative outcomes, GLN-supplemented PN was given during the postoperative period for gastrectomy patients with GC. Consequently, GLN supplementation reduced the rate of infectious complications, improved immune function, and shortened hospital stay. A prospective randomized trial investigated the effect of GLN on postoperative immunosuppression in patients with surgical interventions on esophagus or stomach. Compared with that in the control group without GLN, parenteral GLN or n-3 FA supplementation reversed postoperative immunosuppression, as analyzed by the percentages of T-lymphocyte subsets and human leukocyte antigen-DR isotype (HLA-DR) expression on monocytes. Spittler et al. investigated postoperative glycyl-GLN infusion on HLA-DR expression on monocytes in major abdominal surgery patients. HLA-DR is a gene product of the major histocompatibility complex (MHC) class II antigen. HLA-DR surface antigen expression on monocytes is reduced by surgery and inflammation and is associated with an increased susceptibility to infectious complications. Amino acid solution containing 35 g GLN was infused immediately after surgery and continuously for the next 48 hours. Compared with that in controls without GLN supplementation, giving GLN preserved HLA-DR expression on monocytes, thereby possibly preventing infectious postoperative complications. Moreover, Mochiki et al. investigated postoperative treatment with GLN on GI motor activity in partial distal gastrectomy of patients with GC. Compared with the control, patients receiving oral GLN supplementation (3 g/d) had greater duodenal motor activity and interdigestive migrating motor contractions. Thus, GLN could act as a motility-recovery agent after gastrectomy.

As for animal studies, rats were infused with GLN-containing PN before and after gastrectomy to investigate the efficacy of GLN on surgery. As a result, TPN supplemented with GLN improved nitrogen balance and enhanced abdominal macrophage phagocytic activity in rats with partial gastrectomy. In a previous study, we gave GLN parenterally to investigate the role of GLN on cellular adhesion molecule and inflammatory cell recruitment in rats with total gastrectomy. We found that GLN-enriched PN attenuated leukocyte integrin expression and elicited a more rapid immune response to injury after gastrectomy.

### 2.4 Effects of Arg on gastrectomy

Arginine is a nonessential amino acid that serves as the precursor of various metabolites, such as nitric oxide (NO), citrulline, creatine, ornithine, urea, and polyamines. Arg stimulates anabolic hormone release and improves nitrogen balance. It also shows immunoregulatory characteristics and can attenuate an inflammatory response in stressful conditions. Conversely, Arg deficiency or unavailability inhibits T-lymphocyte proliferation, resulting in diverse impairments in the immune system and response.

### TABLE 1 Studies on enteral immunonutrition in gastrectomy

| Reference      | Immunonutrients        | Time point | Outcomes                                                                 |
|----------------|------------------------|------------|--------------------------------------------------------------------------|
| Braga et al    | Arg, n-3 FA, and RNA   | Perioperation | Advantages in modulating postoperative immune and inflammatory responses |
| Farreras et al | Arg, n-3 FA, and RNA   | Postoperation | Increases collagen synthesis and improves wound healing                 |
| Okamoto et al  | Arg, n-3 FA, and RNA   | Preoperation | Maintains CD4+ T-cell levels, shortens duration of systemic inflammatory response syndrome, and decreases the incidence of postoperative infectious complications |
| Klek et al     | n-3 FA, GLN, and Arg   | Postoperation | Reduces overall morbidity and mortality in malnourished patients           |
| Fujitani et al | Arg, n-3 FA, and RNA   | Preoperation | No benefits in clinical outcomes                                           |
| Liu et al      | GLN and Arg            | Postoperation | Improves nutritional status and immune function                           |
| Sultan et al   | n-3 FA                 | Perioperation | No benefits in clinical outcomes                                           |
| Marano et al   | Arg, n-3 FA, and RNA   | Postoperation | Improves clinical and immunological outcomes                              |
| Kamocki et al  | Arg                    | Perioperation | Increases the fraction of phagocytizing platelets and improves the phagocytic index of thrombocytes |
| Peker et al    | Arg, n-3 FA, and RNA   | Preoperation | Regulates the balance between CD4 and CD8 T cells but increases tumor angiogenesis with prolonged use |
| Ida et al      | EPA                    | Perioperation | No benefits in surgical morbidity and body weight loss                     |
| Li et al       | Arg, GLN, n-3 FA, and nucleotide | Postoperation | Improves immune function and attenuates inflammatory response              |
| Animal study   | BCAA and GLN           | Postoperation | Inhibits muscle atrophy after surgery                                      |
dysfunction is associated with an increased risk of infection in critically ill patients. Arg is considered a conditionally essential amino acid for catabolic patients. However, Arg supplementation remains controversial, especially for patients with sepsis. Although meta-analysis studies found that Arg supplementation has no effect on infectious complications and may deteriorate outcomes in critically ill patients, Arg supplementation is associated with reduced infectious complication rates and a short length of hospital stay with no adverse effects on mortality in patients receiving elective surgery. Recently, in human studies, Arg has been found to decrease clinical infections, postoperative hospital stay, intra-abdominal abscess and anastomotic leak, and mortality. A review reported that the dosage of Arg available in commercial formulations is non-toxic and that parenteral delivery of Arg is also safe at clinical levels. Therefore, Arg should be considered for inclusion in immunonutrient combinations in patients who have suffered trauma and those in acute surgical settings.

Although Arg is a component commonly included in the immunonutrition formula, exclusive use of Arg in clinical trials of major abdominal surgery is rare. To date, Arg supplementation in total gastrectomy has been seldom studied. Kamocki et al investigated the effect of perioperative immunonutrition on platelet phagocytic activity in gastrectomy or laparotomy patients with advanced GC. They found that the phagocytic activity of platelets in advanced GC patients is significantly impaired and perioperative immunonutrition can partially restore platelet phagocytic activity. Compared with perioperative immunonutrition with GLN and n-3 FA, oral Arg supplementation along with adjunct nutritional therapy significantly increased the fraction of phagocytizing platelets and improved the phagocytic index of thrombocytes. In an animal study, Yeh et al evaluated Arg-containing PN on abdominal phagocytic activity in a model of partial gastrectomy. They found that parenteral supplementation of Arg enhanced phagocytic activity and reduced the production of inflammatory mediators after injury. Studies showing the effectiveness of enteral and parenteral immunonutrition on gastrectomy are summarized in Tables 1 and 2.

### 3 | CONCLUSION

In the present review, although we narrowed down the populations of patients to gastrectomy, the findings among the studies have inconsistencies. The fundamental and nutritional status of the recruited patients, the stage and severity of GC, the methods of operation, the intervention dosage, and the time of measuring outcomes are all confounding variables that make each clinical trial different.
from others. Meanwhile, data derived from animal studies cannot be extrapolated to humans, and studies with a small sample size may have a low statistical power that requires cautious interpretation. However, most studies reviewed in this report suggested that immunonutrients that are provided either alone or in combination have favorable effects in improving patient outcomes, except that the exclusive use of arginine is rare and needs to be confirmed in gastrectomy patients with GC. Conventional therapy in combination with immunonutrition pre- and/or postoperatively may be an important strategy to achieve favorable synergistic effects in the management of GC patients.

DISCLOSURE
Conflicts of Interest: Authors declare no conflicts of interest for this article.

ORCID
Jin-Ming Wu https://orcid.org/0000-0002-1821-239X
Ming-Tsan Lin https://orcid.org/0000-0001-7313-7057

REFERENCES
1. Slade MS, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery. 1975;78(3):363–72.
2. Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Br J Surg. 2014;101(10):1209–29.
3. Mazaki T, Ebisawa K. Enteral versus parenteral nutrition after gastrointestinal surgery: a systematic review and meta-analysis of randomized controlled trials in the English literature. J Gastrointest Surg. 2008;12(4):739–55.
4. Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition. 2004;20(10):843–8.
5. Wu MH, Lin MT, Chen WJ. Effect of perioperative parenteral nutritional support for gastric cancer patients undergoing gastrectomy. Hepatogastroenterology. 2008;55(82–83):799–802.
6. Marimuthu K, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of the effect of combinations of immune modulating nutrients pre- and postoperatively in patients undergoing major open gastrointestinal surgery. Ann Surg. 2012;255(6):1060–8.
7. Probst P, Ohmann S, Klaiber U, Hüttner FJ, Billetter AT, Ulrich A, et al. Meta-analysis of immunonutrition in major abdominal surgery. Br J Surg. 2017;104(12):1594–608.
8. Cheng Y, Zhang J, Zhang L, Wu J, Zhan Z. Enteral immunonutrition versus enteral nutrition for gastric cancer patients undergoing a total gastrectomy: a systematic review and meta-analysis. BMC Gastroenterol. 2018;18(1):11.
9. Braga M, Gianotti L, Vignali A, Di Carlo V. Immunonutrition in gastric cancer surgical patients. Nutrition. 1998;14(11–12):831–5.
10. Farreras N, Artigas V, Cardona D, Rius X, Trias M, Gonzalez JA. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr. 2005;24(1):55–65.
11. Marano L, Porfidia R, Pezzella M, Grassia M, Petrillo M, Esposito G, et al. Clinical and immunological impact of early postoperative enteral immunonutrition after total gastrectomy in gastric cancer patients: a prospective randomized study. Ann Surg Oncol. 2013;20(12):3912–8.
12. Okamoto Y, Okano K, Izuishi K, Usuki H, Wakabayashi H, Suzuki Y. Attenuation of the systemic inflammatory response and infectious complications after gastrectomy with preoperative oral arginine and omega-3 fatty acids supplemented immunonutrition. World J Surg. 2009;33(9):1815–21.
13. Fujitani K, Tsujinaka T, Fujita J, Miyashiro I, Imamura H, Kimura Y, et al. Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer. Br J Surg. 2012;99(5):621–9.
14. Klek S, Kulig J, Sierzega M, Szynbinski P, Szczepanek K, Kubisz A, et al. The impact of immunostimulating nutrition on infectious complications after upper gastrointestinal surgery: a prospective, randomized, clinical trial. Ann Surg. 2008;248(2):212–20.
15. Peker KD, Ozkanli SS, Akyuz C, Uzun O, Yasar NF, Duman M, et al. Preoperative immunonutrition regulates tumor infiltrative lymphocytes and increases tumor angiogenesis in gastric cancer patients. Arch Med Sci. 2017;13(6):1365–72.
16. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohoe T, Kawarada Y, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003;63(7):1555–9.
17. Klek S, Sierzega M, Szynbinski P, Szczepanek K, Scislo L, Walewska E, et al. The immunomodulating enteral nutrition in malnourished surgical patients - a prospective, randomized, double-blind clinical trial. Clin Nutr. 2011;30(3):282–8.
18. Liu H, Ling W, Shen ZY, Jin X, Cao H. Clinical application of immune-enhanced enteral nutrition in patients with advanced gastric cancer after total gastrectomy. J Dig Dis. 2012;13(8):401–6.
19. Li K, Xu Y, Hu Y, Liu Y, Chen X, Zhou Y. Effect of enteral immunonutrition on immune, inflammatory markers and nutritional status in gastric cancer patients undergoing gastrectomy: a randomized double-blinded controlled trial. J Invest Surg. 2019;19:1–10.
20. Song G-M, Liu X-L, Bian W, Wu J, Deng Y-H, Zhang H, et al. Systematic review with network meta-analysis: comparative efficacy of different enteral immunonutrition formulas in patients undergoing gastrectomy. Oncotarget. 2017;8(14):23376–88.
21. Haba Y, Fujimura T, Oyama K, Kinoshita J, Miyashita T, Fushiida S, et al. Effect of oral branched-chain amino acids and glutamine supplementation on skeletal muscle atrophy after total gastrectomy in rat model. J Surg Res. 2019;243:281–8.
22. Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr. 2012;142(3):5925–599.
23. Lin MT, Hsu CS, Yeh SL, Yeh CL, Chang KJ, Lee PH, et al. Effects of omega-3 fatty acids on leukocyte Th1/Th2 cytokine and integrin expression in rats with gut-derived sepsis. Nutrition. 2007;23(2):179–86.
24. McCann ME, Moore JN, Carrick JB, Barton MH. Effect of intravenous infusion of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid composition and inflammatory mediator production in vitro. Shock. 2000;14(2):222–8.
25. Ertel W, Keel M, Steckholzer U, Ungethum U, Trentz O. Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia. Arch Surg. 1996;131(1):51–6.
26. Sultan J, Griffin SM, Di Franco F, Kirby JA, Shenton BK, Seal CJ, et al. Randomized clinical trial of omega-3 fatty acid-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing oesophageagastic cancer surgery. Br J Surg. 2012;99(3):346–55.
27. Ida S, Hiki N, Cho H, Sakamaki I, Ito S, Fujitani K, et al. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. Br J Surg. 2017;104(4):377–83.
28. Makay O, Kaya T, Firtat O, Sozbilen M, Caliskan C, Gezer G, et al. omega-3 fatty acids have no impact on serum lactate levels...
after major gastric cancer surgery. JPNEN J Parenter Enteral Nutr. 2011;35(4):488–92.

29. Wei Z, Wang W, Chen J, Yang D, Yan R, Cai Q. A prospective, randomized, controlled study of omega-3 fish oil fat emulsion-based parenteral nutrition for patients following surgical resection of gastric tumors. Nutr J. 2014;13:25.

30. Wu MH, Wang MY, Yang CY, Kuo ML, Lin MT. Randomized clinical trial of new intravenous lipid (SMOFlipid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery. JPNEN J Parenter Enteral Nutr. 2014;38(7):800–8.

31. Lin M-T, Yeh S-L, Yeh C-L, Lai Y-N, Chang K-J, Lee P-H, et al. Parenteral N-3 fatty acids modulate inflammatory and immune response in rats undergoing total gastrectomy. Shock. 2006;25(1):56–60.

32. Wu MH, Tsaı YT, Hua KT, Chang KC, Kuo ML, Lin MT. Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10. J Nutr Biochem. 2012;23(11):1434–9.

33. Lin M-T, Yeh S-L, Kuo M-L, Liaw K-Y, Lee P-H, Chang K-J, et al. Effects of medium-chain triglyceride in parenteral nutrition on rats undergoing gastrectomy. Clin Nutr. 2002;21(1):39–43.

34. Chambrier C, Guiraud M, Gibault JP, Labrosse H, Bouletreau P. Medium- and long-chain triacylglycerols in postoperative patients: structured lipids versus a physical mixture. Nutrition. 1999;15(4):274–44.

35. Kruimel JW, Naber TH, van der Vliet JA, Carneheim C, Katan MB, Jansen JB. Parenteral structured triglyceride emulsion improves nitrogen balance and is cleared faster from the blood in moderately catabolic patients. JPNEN J Parenter Enteral Nutr. 2001;25(5):237–44.

36. Lin MT, Yeh SL, Tsou SS, Wang MY, Chen WJ. Effects of parenteral structured lipid emulsion on modulating the inflammatory response in rats undergoing a total gastrectomy. Nutrition. 2009;25(1):115–21.

37. Labow BI, Soubia WW. Glutamine. World J Surg. 2000;24(12):1503–13.

38. Wischmeyer PE. Glutamine: mode of action in critical illness. Crit Care Med. 2007;35(9 Suppl):S541–S544.

39. Curi R, Lagranha CJ, Doi SQ, Selliatti DF, Procopio J, Pithon-Curi TC, et al. Molecular mechanisms of glutamine action. J Cell Physiol. 2005;204(2):392–401.

40. Klek S, Kulig J, Szczepanik AM, Jedrys J, Kolodziejczyk P. The clinical value of parenteral immunonutrition in surgical patients. Acta Chir Belg. 2005;105(2):175–9.

41. Jacobi CA, Ordemann J, Zuckermann H, Docke W, Volk HD, Muller JM. The influence of alanyl-glutamine on immunologic functions and morbidity in postoperative parenteral nutrition. Preliminary results of a prospective randomized trial. Zentralbl Chir. 1999;124(3):199–205.

42. Spittler A, Saunder T, Gornikiewicz A, Manhart N, Oehler R, Bergmann M, et al. Postoperative glycyl-glutamine infusion reduces immunosuppression: partial prevention of the surgery induced decrease in HLA-DR expression on monocytes. Clin Nutr. 2001;20(1):37–42.

43. Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg. 1993;80(2):205–9.

44. Mochiki E, Ohno T, Yanai M, Toyomatsu Y, Andoh H, Kuwano H. Effects of glutamine on gastrointestinal motor activity in patients following gastric surgery. World J Surg. 2011;35(4):805–10.

45. Lee CH, Chiu WC, Chen SC, Wu CH, Yeh SL. Effects of glutamine-containing total parenteral nutrition on phagocytic activity and anabolic hormone response in rats undergoing gastrectomy. World J Gastroenterol. 2005;11(6):817–22.

46. Lin MT, Chou SY, Tsou SS, Wang MY, Wu MH, Yeh SL. Effects of parenteral glutamine supplementation on modulating the immune response in rats undergoing a total gastrectomy. Br J Nutr. 2009;102(4):520–5.

47. Patel JJ, Miller KR, Rosenthal CA, Rosenthal MD. When is it appropriate to use arginine in critical illness? Nutr Clin Pract. 2016;31(4):438–44.

48. Kirk SJ, Barbul A. Role of arginine in trauma, sepsis, and immunity. JPNEN J Parenter Enteral Nutr. 1990;14(5 Suppl):226S–S229.

49. Yeh CL, Hu YM, Liu JJ, Chen WJ, Yeh SL. Effects of supplemental dietary arginine on the exogenous advanced glycosylation end product-induced interleukin-23/interleukin-17 immune response in rats. Nutrition. 2012;28(10):1063–7.

50. Kuo YF, Yeh CL, Shih JM, Shih YM, Yeh SL. Arginine pretreatment enhances circulating endothelial progenitor cell population and attenuates inflammatory response in high-fat diet-induced obese mice with limb ischemia. Nutr Res. 2018;53:67–76.

51. Bansal V, Ochoa JB, Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care. 2003;6(2):223–8.

52. Zhu X, Pribis JP, Rodriguez PC, Morris SM, Vodovotz Y, Billiar TR, et al. The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg. 2014;259(1):171–8.

53. Zhou M, Martindale RG. Arginine in the critical care setting. J Nutr. 2007;137(6 Suppl 2):1687S–S1692.

54. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009;157(6):922–30.

55. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA. 2001;286(8):944–53.

56. Rosenthal MD, Vanzant EL, Martindale RG, Moore FA. Evolving paradigms in the nutritional support of critically ill surgical patients. Curr Probl Surg. 2015;52(4):147–82.

57. Rosenthal MD, Carroll PW, Patel J, Kiraly L, Martindale RG. Parenteral or enteral arginine supplementation safety and efficacy. J Nutr. 2016;146(12):2594S–S2600.

58. Kamocki Z, Matowicka-Karna J, Gryko M, Zareba K, Kedra B, Kemona H. The effect of perioperative immunonutrition on the phagocytic activity of blood platelets in advanced gastric cancer patients. Clin Dev Immunol. 2013;2013:435672.

59. Yeh CL, Lee CH, Chen SC, Hou YC, Yeh SL. Effects of arginine-containing total parenteral nutrition on N balance and phagocytic activity in rats undergoing a partial gastrectomy. Br J Nutr. 2005;93(2):267–72.